发明名称 |
FUSION PROTEIN HAVING ENHANCED IN VIVO ERYTHROPOIETIN ACTIVITY |
摘要 |
Provided is a fusion protein comprising, at its carboxy terminal of human erythropoietin (EPO), a mutant having one to four amino acid substitutions in the carboxy terminal peptide (CTP) fragment of a human chorionic gonadotropin (HCG) beta subunit, for increasing an in vivo half-life activity of EPO. The in vivo half-life can be greatly elongated while retaining the intrinsic activity of the EPO, without increasing the sugar chain content.
|
申请公布号 |
WO03048210(A1) |
申请公布日期 |
2003.06.12 |
申请号 |
WO2002KR01493 |
申请日期 |
2002.08.06 |
申请人 |
CHEIL JEDANG CORPORATION |
发明人 |
LEE, DONG-EOK;OH, MYUNG-SUK;KIM, KI-WAN;CHUNG, BO-SUP;PARK, JI-SOOK |
分类号 |
C12N15/02;A61K38/00;A61P7/06;A61P43/00;C07K14/505;C07K14/59;C07K19/00;C12N15/00;C12N15/62;C12P21/00;C12P21/02;(IPC1-7):C07K19/00 |
主分类号 |
C12N15/02 |
代理机构 |
|
代理人 |
|
主权项 |
|
地址 |
|